Overeating on Wegovy: what actually happens and why it still occurs

The myth worth clearing up first: Wegovy does not simply switch off appetite

A lot of people start Wegovy expecting hunger to disappear entirely. For some it very nearly does, particularly during the early weeks. For others, the reduction is meaningful but not total, and eating past fullness remains possible, especially at higher doses when nausea is more pronounced but psychological drivers of eating are unaffected. The medicine targets GLP-1 receptors in the hypothalamus (the part of the brain that regulates satiety) and in the gut, which is why fullness signals arrive earlier and persist longer. But those signals can still be overridden. Eating quickly, eating while distracted, responding to stress or boredom, or sitting down to a social meal where stopping feels awkward, none of these are switched off by a weekly injection.

The NHS semaglutide medicines page notes that Wegovy works alongside a reduced-calorie diet and increased physical activity. That framing matters: it acknowledges that the medicine is a support, not a substitute for behavioural change. If you're relying on it to do all the work, you may find overeating continues more than you hoped.

Exploring what eating on Wegovy typically looks like can help set more realistic expectations from the start.

What overeating on Wegovy actually feels like

Here is where things get genuinely different from overeating without the medicine. Because gastric emptying slows on semaglutide, food stays in the stomach longer. Eat past the point of fullness and the consequences are often sharper: pronounced nausea, bloating, reflux or vomiting that can last several hours. Some people describe this as an accidental feedback loop, they overeat once, feel genuinely awful, and find portion control easier for a while afterwards. That feedback is real, but it is not a comfortable or reliable learning mechanism, and it is not how the treatment is designed to work.

Common side effects during the early months (nausea, burping, indigestion) tend to be most noticeable in the first few weeks or after a dose increase, and generally settle as the body adjusts. The discomfort of overeating on top of those baseline effects can be significant. If side effects are severe or persistent, that is a conversation for your prescriber, not something to manage alone.

If you are finding you consistently cannot eat enough rather than too much, that is worth discussing too, both ends of the spectrum are relevant to how well treatment is going.

Why emotional and habitual eating persists

Physical hunger and the urge to eat are not the same thing. Wegovy addresses the former far more reliably than the latter. Eating in response to stress, tiredness, anxiety, boredom or habit does not require a hunger signal, it can happen when you feel completely full. This is one of the most common sources of wegovy overeating that patients and prescribers discuss together, and it is not a moral failing. It reflects patterns that took years to build and are not dismantled by a change in gut hormones.

Behavioural support alongside the medicine (whether that is working with a dietitian, using a structured eating plan, or simply becoming more deliberate about the conditions in which you eat (seated, away from a screen, no eating straight from packaging)) consistently produces better outcomes than medication alone. Keeping meals relatively structured and your pen in the fridge door as a visible reminder of your commitment to the plan can seem small, but routine reinforces intention.

For a deeper look at what to eat and how to structure meals, this guide on food choices during Wegovy treatment covers practical strategies grounded in clinical guidance. Thinking about private treatment costs is also reasonable at this stage, a clear breakdown of what Wegovy costs privately helps you plan.

When to speak to your prescriber

Occasional overeating that causes temporary discomfort is one thing. Repeated episodes, persistent nausea that does not settle, or a sense that appetite suppression is not working at all are worth raising before your next scheduled review. A prescriber may consider whether the titration schedule needs adjusting, whether the current dose is appropriate, or whether additional behavioural support would help. The NICE appraisal of Wegovy (TA875) recommends treatment within a framework that includes diet and lifestyle support precisely because the evidence base was built on that combination.

At nume, a named clinician reviews your case before every repeat order, not a form that gets rubber-stamped, but an actual prescriber reading your update. If something is not working, that is exactly the point at which the review is designed to catch it. You can read more about how Wegovy works or, when you're ready, start a free consultation to discuss whether it is the right option for you.